Dallas, Texas, USA, October 16th, 2026, FinanceWire

Today's corporate developments highlight some very different investment narratives: NeOnc Technologies Holdings (NASDAQ:NTHI) is pursuing new avenues for experimental brain-cancer treatments, Alector (NASDAQ:ALEC) is raising fresh capital for neurological disease research, Alaunos Therapeutics (NASDAQ:TCRT) is repositioning around pulmonary hypertension through a major acquisition, Zenta Group (NASDAQ:ZTG) is pursuing an artificial intelligence and data-services strategy, and Exascale Labs (NASDAQ:XLAB) is seeking to convert surging AI-computing demand into commercial growth.

Mobilicom (NASDAQ: MOB) is a provider of robust end-to-end hardware and software solutions for defense and commercial drones, robotics, and autonomous systems. The company serves original equipment manufacturers (“OEMs”) seeking to keep unmanned platforms connected, protected, and operational during demanding missions, including in environments exposed to interference and cyber threats. Its business combines proprietary hardware […]

Alaunos Therapeutics (NASDAQ:TCRT) completed its acquisition of Velaris Therapeutics and secured approximately $350 million in gross private-placement proceeds, setting up an aggressive push into pulmonary arterial hypertension (PAH) with a clinical pipeline targeting multiple disease-driving pathways.